Any current/future new fundraising through debt or equity?

The company currently has a low debt level of around 0.27% on a consolidated basis and is not planning to expand debt except for: - A line of credit close to Rs. 40 crores already taken for the radiation business, which will be utilized by the end of Q1. - Working capital investments for the implant business that will continue for one or two more quarters. There is no mention of planned equity fundraising. The company is focusing on optimizing costs and improving EBITDA without significant new debt. For the implant business, ongoing investment in working capital is expected, but major expa

Any current/future capex/capital investment/strategic investment?

Current plant is reaching full capacity; focus is on maximizing utilization by adding shifts and labor rather than adding new plants to avoid extra CAPEX. Minimal CAPEX of Rs. 50-100 crores planned to almost double top-line within existing bed capacity. Adding two LINAC bunkers (one in Ahmedabad, one in Surat) for high-end radiation oncology services, representing an area of growth. Continuous investment in implant business working capital and product development, including new product approvals (e.g., U.S. FDA, CDSCO for robotic surgeries and bone cement). No immediate plans for new offshore

Future growth expectations in sales/revenue/volumes?

Hospital business expects double-digit revenue growth for the next 4-5 years, leveraging existing bed capacity and minimal CAPEX (Rs. 50-100 crores) for expansion. Inpatient and outpatient counts are projected to grow in double digits (8-10% occupancy growth long term). Oncology segment is rapidly growing, now second highest revenue contributor, with ongoing investments in radiation and surgical oncology. Implant business targets multi-fold growth next financial year, fueled by new U.S. FDA-approved products like CKS TiNbN knee (Duraniom) and others launching soon. Sales in implant bus

Future growth expectations in earnings/operating earnings/profits/EPS?

Hospital business is expected to continue double-digit growth in revenue and EBITDA, supported by expansion and increased occupancy. (Pages 19, 22, 23) ARPOB (Average Revenue Per Occupied Bed) growth is projected between 3% to 6%, with volume growth of 8% to 10%, leading to overall double-digit inpatient and outpatient growth. (Page 23) Implant business (Shalby Advanced Technologies/MedTech) is set for multi-fold growth in FY26 due to new product approvals (e.g., CKS TiNbN knee - Duraniom) and global expansion, targeting a $100 million business over five years. (Pages 8, 15, 17) EBITDA margins

Shalby LtdQ3 FY25Healthcare Services

Shalby Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹129P/E: 35.4Market Cap: ₹1.4K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Hospital business expects double-digit revenue growth for the next 4-5 years, leveraging existing bed capacity and minimal CAPEX (Rs. 50-100 crores) for expansion.
Inpatient and outpatient counts are projected to grow in double digits (8-10% occupancy growth long term).
Oncology segment is rapidly growing, now second highest revenue contributor, with ongoing investments in radiation and surgical oncology.
Implant business targets multi-fold growth next financial year, fueled by new U.S. FDA-approved products like CKS TiNbN knee (Duraniom) and others launching soon.
Sales in implant business have grown 25% year-on-year; strong demand in global markets including U.S., Indonesia, and India.
Overall consolidated revenue grew 27.4% Y-o-Y in Q3, with increasing volumes and continuous product portfolio expansion expected to support this trajectory.
Future focus includes new product launches, capacity scaling, and market expansion across Asia, Latin America, and other global regions.

Margin guidance

Category 3

Hospital business is expected to continue double-digit growth in revenue and EBITDA, supported by expansion and increased occupancy. (Pages 19, 22, 23)
ARPOB (Average Revenue Per Occupied Bed) growth is projected between 3% to 6%, with volume growth of 8% to 10%, leading to overall double-digit inpatient and outpatient growth. (Page 23)
Implant business (Shalby Advanced Technologies/MedTech) is set for multi-fold growth in FY26 due to new product approvals (e.g., CKS TiNbN knee - Duraniom) and global expansion, targeting a $100 million business over five years. (Pages 8, 15, 17)
EBITDA margins of around 21%-22% for the standalone hospital business are expected to be sustainable, with ongoing cost optimization. (Page 19)
Sanar Hospital is expected to turn EBITDA positive shortly and profitability improvement is anticipated in the next financial year. (Pages 10, 17)
Overall consolidated tax rate to normalize post-MAT exhaustion in FY25. (Page 11)

See what Shalby Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company currently has a low debt level of around 0.27% on a consolidated basis and is not planning to expand debt except for:
- A line of credit close to Rs. 40 crores already taken for the radiation business, which will be utilized by the end of Q1.
- Working capital investments for the implant business that will continue for one or two more quarters.
There is no mention of planned equity fundraising.
The company is focusing on optimizing costs and improving EBITDA without significant new debt.
For the implant business, ongoing investment in working capital is expected, but major expansion and CAPEX additions are being controlled.
The conservative approach reflects a preference for maximizing current asset utilization before adding new capacity or incurring more CAPEX/debt.

Order book

- The transcript provided does not explicitly mention the current or expected order book or pending orders for Shalby Limited. - However, insights into business outlook and pipeline include: - Implant business shows significant growth potential, aiming for $100 million in five years in a $30 billion global market. - Device business (Implants) is experiencing growth, with expanding manufacturing capacity and reduction in COGS. - Franchise-operated low-cost hospital model currently has 5 operational franchises with plans to expand selectively once management bandwidth allows. - No specific active announcements on new hospital outlets in the near term but some opportunities are in the pipeline. - The company focuses on consolidating current operations before aggressive expansion. - Overall, growth driven by double-digit inpatient and outpatient growth, supported by acquisitions (e.g., Sanar) and new product launches. No direct mention of orderbook value or pending orders was disclosed in the Q3 FY25 earnings call transcript.

See what Shalby Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Current plant is reaching full capacity; focus is on maximizing utilization by adding shifts and labor rather than adding new plants to avoid extra CAPEX.
Minimal CAPEX of Rs. 50-100 crores planned to almost double top-line within existing bed capacity.
Adding two LINAC bunkers (one in Ahmedabad, one in Surat) for high-end radiation oncology services, representing an area of growth.
Continuous investment in implant business working capital and product development, including new product approvals (e.g., U.S. FDA, CDSCO for robotic surgeries and bone cement).
No immediate plans for new offshore manufacturing plants until quality and scale are proven in the current facility.
Future potential to replicate manufacturing in India or other countries once scale and quality are established.
Conservative approach on hospital expansion; focus on consolidating current operations before aggressive scaling.

Track Shalby Ltd — get its next earnings analysis in your feed

How does Shalby Ltd rank vs peers in Healthcare Services?

Pro feature

ThisShalby Ltd

Rev 3Mar 3

See where Shalby Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Shalby Ltd rank in Healthcare Services?

Compare Shalby Ltd against every Healthcare Services company (Q3 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Shalby's management said in earlier quarters

Others in Healthcare Services this season

Aatmaj Healthcare Ltd (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
Maitreya Medica. (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medica.'s Q2 FY26 investor presentation — and how it ranks against sector peers.
Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
Suven Life Scie. (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su

Compare:vs Apollo Hospitals vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Shalby Ltd Q3 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Shalby Ltd rank in Healthcare Services?

Continue your research

What Shalby's management said in earlier quarters

Others in Healthcare Services this season